Attenuated Salmonella carrying siRNA-CD24 improved the effect of oxaliplatin on HCC.

Int Immunopharmacol

Department of Oncology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453000, PR China; Xinxiang Engineering Technology Research Center of Immune Checkpoint Drug for Liver-Intestinal Tumors, Xinxiang Medical University, Xinxiang, Henan 453000, PR China; Department of Pathology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan 453000, PR China. Electronic address:

Published: November 2023

AI Article Synopsis

  • * Tumor-associated macrophages are linked to poor prognosis and resistance to oxaliplatin, making them a potential target for improving treatment strategies, particularly in hepatocellular carcinoma (HCC).
  • * The study used RNAi technology to block CD24 in tumor cells alongside oxaliplatin, leading to reduced tumor growth and improved immune response, suggesting a new combination therapy for HCC.

Article Abstract

Oxaliplatin is a chemotherapy drug currently utilized in the treatment of advanced cancer patients. However, its tolerability poses a limitation to its clinical application. Studies have demonstrated that the presence of tumor-associated macrophages is positively correlated with poor prognosis in various solid tumors, including hepatocellular carcinoma (HCC), and is a significant factor contributing to oxaliplatin resistance. Therefore, targeting tumor-associated macrophages may be an effective strategy to improve the efficacy of oxaliplatin in the treatment of HCC patients. CD24 is a novel target for tumor therapy that can interact with the inhibitory receptor Siglec-10 on tumor-associated macrophages, transmitting immune inhibitory signals and inhibiting macrophage phagocytosis function. In this study, we utilized RNAi technology to inhibit the expression of CD24 in tumor cells and combined it with oxaliplatin, resulting in reduced tumor invasion, migration, and proliferation, as well as increased cell apoptosis. Furthermore, immunofluorescence and flow cytometry results indicated that both the single treatment group and combination treatment group enhanced the infiltration of immune cells. This study presents a novel approach to identifying combination therapy and targets for the clinical treatment of HCC with oxaliplatin.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.intimp.2023.111025DOI Listing

Publication Analysis

Top Keywords

tumor-associated macrophages
12
hcc oxaliplatin
8
treatment hcc
8
treatment group
8
oxaliplatin
6
treatment
5
attenuated salmonella
4
salmonella carrying
4
carrying sirna-cd24
4
sirna-cd24 improved
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!